A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and
5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and
symptoms of benign prostatic hyperplasia (BPH) in men with both ED and signs and symptoms of
BPH.